Anti-CD19 antibodies and uses in oncology
2 Assignments
0 Petitions
Accused Products
Abstract
The invention relates to immunotherapeutic compositions and methods for the treatment of B cell diseases and disorders in human subjects, such as, but not limited to, B cell malignancies, using therapeutic antibodies that bind to the human CD19 antigen and that preferably mediate human ADCC. The present invention relates to pharmaceutical compositions comprising human or humanized anti-CD19 antibodies of the IgG1 or IgG3 human isotype. The present invention relates to pharmaceutical compositions comprising human or humanized anti-CD19 antibodies of the IgG2 or IgG4 human isotype that preferably mediate human ADCC. The present invention also relates to pharmaceutical compositions comprising chimerized anti-CD19 antibodies of the IgG1, IgG2, IgG3, or IgG4 isotype that mediate human ADCC. In preferred embodiments, the present invention relates to pharmaceutical compositions comprising monoclonal human, humanized, or chimeric anti-CD19 antibodies.
96 Citations
74 Claims
-
1-27. -27. (canceled)
-
28. A method of treating a B cell malignancy in a human patient comprising;
administering a therapeutically effective regimen of a monoclonal human or humanized anti-CD19 antibody that mediates human antibody-dependent cellular cytotoxicity (ADCC), to a human patient in need of such treatment. - View Dependent Claims (29, 35, 36, 37, 41, 42, 51, 58, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74)
-
30-34. -34. (canceled)
-
38-40. -40. (canceled)
-
43-50. -50. (canceled)
-
52-57. -57. (canceled)
-
59-63. -63. (canceled)
Specification